Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 364 | 25 | 338 |
| Samples | 234 | 21 | 212 |
| Peptides | 207 | 16 | 195 |
Function
PIM1 · Pim-1 proto-oncogene, serine/threonine kinase
The protein encoded by this gene belongs to the Ser/Thr protein kinase family, and PIM subfamily. This gene is expressed primarily in B-lymphoid and myeloid cell lines, and is overexpressed in hematopoietic malignancies and in prostate cancer. It plays a role in signal transduction in blood cells, contributing to both cell proliferation and survival, and thus provides a selective advantage in tumorigenesis. Both the human and orthologous mouse genes have been reported to encode two isoforms (with preferential cellular localization) resulting from the use of alternative in-frame translation initiation codons, the upstream non-AUG (CUG) and downstream AUG codons (PMIDs:16186805, 1825810).[provided by RefSeq, Aug 2011].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000373509 | P11309 | 364 | 207 |
Gene Properties
Recurrent Mutations
All 207 amino-acid changes on canonical ENST00000373509 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in PIM1 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in PIM1 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Cell Non-Hodgkins Lymphoma | 2/26 8% | 0/0 0% |
| B-Cell Non-Hodgkins Lymphoma | 3/88 3% | 88/2534 3% |
| Unknown | 1/10 10% | 0/29 0% |
| Hodgkins Lymphoma | 0/16 0% | 3/122 2% |
| Endometrial Carcinoma | 0/42 0% | 8/612 1% |
| Plasma Cell Myeloma | 0/44 0% | 3/305 1% |
| Melanoma | 2/210 1% | 14/1899 1% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 1/133 1% |
| Other Blood Cancers | 1/61 2% | 20/2725 1% |
| Burkitts Lymphoma | 0/32 0% | 1/196 1% |
| Head and Neck Carcinoma | 2/85 2% | 5/1574 0% |
| Meningioma | 0/3 0% | 1/252 0% |
| Gastric Carcinoma | 2/74 3% | 5/1809 0% |
| Colorectal Carcinoma | 1/143 1% | 11/3239 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 9/2550 0% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 3/810 0% |
| Bladder Carcinoma | 0/58 0% | 3/956 0% |
| Non-Small Cell Lung Carcinoma | 3/304 1% | 2/1390 0% |
| Neuroendocrine Tumour | 0/154 0% | 2/577 0% |
| Other Sarcomas | 0/69 0% | 2/699 0% |
| Esophageal Carcinoma | 0/23 0% | 2/769 0% |
| Other Solid Cancers | 0/94 0% | 4/1515 0% |
| Glioma | 0/52 0% | 5/2127 0% |
| Hepatocellular Carcinoma | 0/46 0% | 5/2210 0% |
| Cervical Carcinoma | 0/35 0% | 1/422 0% |
| Biliary Tract Carcinoma | 0/54 0% | 2/950 0% |
| Pancreatic Carcinoma | 0/89 0% | 3/1611 0% |
| Ovarian Carcinoma | 2/109 2% | 0/998 0% |
| B-Lymphoblastic Leukemia | 2/55 4% | 2/2640 0% |
| Prostate Carcinoma | 0/13 0% | 3/2105 0% |
Mutation Distribution
Where PIM1 is mutated · all tissues, split by cell line vs tissue
How many mutations in PIM1 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 364 mutations in PIM1
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|